D. Monfort

发表

Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.

M. Navasa, V. Arroyo, E. Quintero, 2007, Gastroenterology.

Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn's disease (ProtDilat study): an open-label, multicentre, randomised trial.

D. Busquets, J. Barrio, V. Sánchiz, 2022, The lancet. Gastroenterology & hepatology.

New Methylation Biomarker Panel for Early Diagnosis of Dysplasia or Cancer in High-Risk Inflammatory Bowel Disease Patients.

E. Guinó, V. Moreno, G. Capellá, 2018, Inflammatory bowel diseases.

Novel Methylation Panel for the Early Detection of Neoplasia in High-risk Ulcerative Colitis and Crohn's Colitis Patients

M. Esteller, V. Moreno, G. Capellá, 2013, Inflammatory bowel diseases.

Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn’s disease

A. Salar, M. Andreu, X. Bessa, 2007, Gut.

High smoking cessation rate in Crohn's disease patients after physician advice--the TABACROHN Study.

M. Sans, F. Gomollón, L. Menchen, 2013, Journal of Crohn's & colitis.

Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study

J. Gisbert, I. Bastón-Rey, D. Busquets, 2022, Inflammatory Bowel Diseases.

TNFα production to TLR2 ligands in active IBD patients

J. Rodríguez-Sánchez, E. Cantó, S. Vidal, 2006 .

291 Hemodynamic response to beta-blockers and prediction of clinical efficacy in the primary prophylaxis of variceal bleeding in patients with cirrhosis

B. González, X. Torras, C. Villanueva, 2003 .

Does Smoking Influence Crohn's Disease in the Biologic Era? The TABACROHN Study

M. Sans, F. Gomollón, L. Menchen, 2013, Inflammatory bowel diseases.

Serum and ascitic fluid bacterial DNA: A new independent prognostic factor in noninfected patients with cirrhosis

J. González-Navajas, M. Serra, P. Zapater, 2008, Hepatology.

Real‐world short‐term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry

J. Gisbert, L. Bujanda, A. Gutiérrez, 2019, Alimentary pharmacology & therapeutics.

Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study

J. Gisbert, X. Calvet, M. Chaparro, 2016, Inflammatory bowel diseases.

Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case‐control study

J. Gisbert, X. Calvet, E. Cabré, 2018, Alimentary pharmacology & therapeutics.

[Use of adalimumab in a patient with Crohn's disease and extensive generalised psoriasis who achieved complete remission of both conditions].

M. Piqueras, J. Boadas, I. Modolell, 2013, Gastroenterologia y hepatologia.

330 High Smoking Cessation Rate in Crohns Disease Patients Attending a Multicenter Anti-Tobacco Program: the TABACROHN Study

M. Sans, F. Gomollón, L. Menchen, 2012 .

Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry

J. Gisbert, X. Calvet, M. Piqueras, 2021, Journal of Crohn's & colitis.

Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

J. Gisbert, X. Calvet, J. Tosca, 2017, The American Journal of Gastroenterology.

Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease.

J. Gisbert, X. Calvet, M. Chaparro, 2016, Gastroenterologia y hepatologia.

Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry.

J. Gisbert, X. Calvet, M. Dominguez-Cajal, 2019, Inflammatory bowel diseases.

EFFECTIVENESS AND SAFETY OF THE SEQUENTIAL USE OF A SECOND AND THIRD ANTI-TNF AGENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY SHORT TITLE: Sequential use of anti-TNFs in IBD patients AUTHORS

Mariana, J. Gisbert, X. Calvet, 2020 .

Evaluation of 5 versus 10 granulocyteaphaeresis sessions in steroid-dependent ulcerative colitis: a pilot, prospective, multicenter, randomized study.

F. Casellas, M. Sans, J. Panés, 2007, World journal of gastroenterology.

114 Randomized, double-blind, placebo-controlled trial evaluating norfloxacin in the primary prophylaxis of spontaneous bacterial peritonitis in cirrhotics with renal impairment, hyponatremia or severe liver failure

M. Navasa, V. Arroyo, E. Quintero, 2006 .

A Case of Vulvar Pyoderma Gangrenosum Associated with Collagenous Colitis

E. Roé, D. Busquets, J. Dalmau, 2006, Dermatology.

Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study.

M. Sans, X. Calvet, L. Bujanda, 2010, Journal of Crohn's & colitis.

Switching to a second thiopurine in adult and elderly patients with inflammatory bowel disease: a nationwide study from the ENEIDA registry.

J. Gisbert, X. Calvet, S. Riestra, 2020, Journal of Crohn's & colitis.

Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry

X. Calvet, L. Bujanda, J. Barrio, 2019, Surgical Endoscopy.

Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu

J. Gisbert, I. Bastón-Rey, M. Chaparro, 2021, Journal of clinical medicine.

Impact of Smoking Cessation on the Clinical Course of Crohn’s Disease Under Current Therapeutic Algorithms: A Multicenter Prospective Study

M. Sans, J. Panés, F. Gomollón, 2016, The American Journal of Gastroenterology.

TNF alpha production to TLR2 ligands in active IBD patients.

J. Rodríguez-Sánchez, E. Cantó, S. Vidal, 2006, Clinical immunology.

Effectiveness of a Dose “De-Escalation” Strategy With Anti-TNF Drugs in Patients With Crohn's Disease (CD)

J. Gisbert, X. Calvet, M. Chaparro, 2011 .

Endoscopic treatment (endoscopic balloon dilation/self-expandable metal stent) vs surgical resection for the treatment of de novo stenosis in Crohn’s disease (ENDOCIR study): an open-label, multicentre, randomized trial

C. Tebé, D. Busquets, M. Millan, 2023, Trials.

Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

J. Gisbert, I. Bastón-Rey, D. Busquets, 2022, Journal of clinical medicine.

Influence of a nucleotide oligomerization domain 1 (NOD1) polymorphism and NOD2 mutant alleles on Crohn's disease phenotype.

J. Rodríguez-Sánchez, D. Busquets, E. Cantó, 2007, World journal of gastroenterology.

OP034 The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case–control study of the ENEIDA registry

J. Gisbert, X. Calvet, J. Panés, 2018 .